Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATE versus U GENCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATE versus U GENCIN.
NEOMYCIN AND POLYMYXIN B SULFATE vs U-GENCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Polymyxin B sulfate is a cationic detergent that disrupts bacterial cell membrane permeability by interacting with phospholipids, leading to cell death.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
For irrigation of urinary bladder: 1 mL of solution containing 40 mg neomycin and 200,000 units polymyxin B per mL diluted in 1 liter of 0.9% sodium chloride, instilled via continuous irrigation at a rate of 1 liter per 24 hours. For topical use: apply thin layer to affected area 2-4 times daily.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
None Documented
None Documented
Neomycin: 2-3 hours (normal renal function), prolonged to 24-48 hours in renal impairment; Polymyxin B: 4.5-6 hours (normal renal function), extended significantly in renal failure.
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Renal: ~90-95% (neomycin, polymyxin B) unchanged; fecal: 5-10% (biliary excretion negligible).
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic